These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 2596685)
1. Preparation of theatres for malignant hyperpyrexia patients. McKenzie A; Pollock N Anaesth Intensive Care; 1989 Nov; 17(4):510-1. PubMed ID: 2596685 [No Abstract] [Full Text] [Related]
2. [Comparative evaluation of the operating room contamination by fluorothane vapors from semiclosed and closed respiratory circuits]. Dateshidze KT; Kas'ianova AV Anesteziol Reanimatol; 1979; (5):32-4. PubMed ID: 507432 [No Abstract] [Full Text] [Related]
3. [The concentrations of halothane in the operating theatre and its dependance on various methods of removal (author's transl)]. Hövener B; Link J Anaesthesist; 1976 Feb; 25(2):68-71. PubMed ID: 1267117 [TBL] [Abstract][Full Text] [Related]
4. Malignant hyperthermia and the clean machine. McGraw TT; Keon TP Can J Anaesth; 1989 Sep; 36(5):530-2. PubMed ID: 2791177 [TBL] [Abstract][Full Text] [Related]
5. Pollution in operating theatres: Part 2: The solution. Holmes CM N Z Med J; 1978 Jan; 87(604):50-4. PubMed ID: 273795 [No Abstract] [Full Text] [Related]
6. The effect of ventilation system design on air contamination with halothane in operating theatres. Langley DR; Steward A Br J Anaesth; 1974 Oct; 46(10):736-41. PubMed ID: 4621196 [No Abstract] [Full Text] [Related]
8. An occupational health approach to anaesthetic air pollution. Hunter L Med J Aust; 1976 Apr; 1(14):465-8. PubMed ID: 933919 [TBL] [Abstract][Full Text] [Related]
9. Influence of gas flows and operating room ventilation on the daily exposure of anesthetists to halothane. Usubiaga L; Aldrete JA; Fiserova-Bergerova V Anesth Analg; 1972; 51(6):968-74. PubMed ID: 4673938 [No Abstract] [Full Text] [Related]
10. Letter: New causes of malignant hyperpyrexia. Lack JA Br Med J; 1975 Jan; 1(5948):36-7. PubMed ID: 1120228 [No Abstract] [Full Text] [Related]
12. [Contamination of air in operating rooms during halothane anesthesia]. Brendstrup A Ugeskr Laeger; 1972 Feb; 134(8):388-90. PubMed ID: 5047058 [No Abstract] [Full Text] [Related]
14. A protocol to manage malignant hyperthermia with general anesthesia. Roberts MW Pediatr Dent; 1993; 15(1):45-6. PubMed ID: 7901841 [No Abstract] [Full Text] [Related]
18. [Postoperative hyperthermic syndrome with a questionable relationship to malignant hyperthermia and the need for elucidating susceptibility]. Plötz J Anaesthesist; 1986 Dec; 35(12):751-4. PubMed ID: 3826611 [TBL] [Abstract][Full Text] [Related]
19. [Determination of subanesthetic concentrations of halothane in the environment of operating and recovery rooms]. Unceta-Barenechea Orúe B; Serna de Andrés A; Garrán Sabando B; Vicinay Pinedo S; Seoane de Lucas A Rev Esp Anestesiol Reanim; 1989; 36(3):171-3. PubMed ID: 2762613 [TBL] [Abstract][Full Text] [Related]
20. Recent advances in the understanding of anaesthetic-induced malignant hyperpyrexia. Harrison GG Anaesthesist; 1973 Aug; 22(8):373-6. PubMed ID: 4749220 [No Abstract] [Full Text] [Related] [Next] [New Search]